MedPath

acamprosate calcium

ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004

Approved
Approval ID

0c729939-d2d2-4e61-acbc-4f1646dc38c1

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Nov 6, 2023

Manufacturers
FDA

Zydus Lifesciences Limited

DUNS: 918596198

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

acamprosate calcium

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code70771-1057
Application NumberANDA205995
Product Classification
M
Marketing Category
C73584
G
Generic Name
acamprosate calcium
Product Specifications
Route of AdministrationORAL
Effective DateNovember 6, 2023
FDA Product Classification

INGREDIENTS (11)

ACAMPROSATE CALCIUMActive
Quantity: 333 mg in 1 1
Code: 59375N1D0U
Classification: ACTIB
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
POLYETHYLENE GLYCOL 8000Inactive
Code: Q662QK8M3B
Classification: IACT
METHACRYLIC ACIDInactive
Code: 1CS02G8656
Classification: IACT
CELLULOSE, MICROCRYSTALLINEInactive
Code: OP1R32D61U
Classification: IACT
SODIUM BICARBONATEInactive
Code: 8MDF5V39QO
Classification: IACT
POVIDONE K90Inactive
Code: RDH86HJV5Z
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
SODIUM LAURYL SULFATEInactive
Code: 368GB5141J
Classification: IACT
SODIUM STARCH GLYCOLATE TYPE A POTATOInactive
Code: 5856J3G2A2
Classification: IACT
TALCInactive
Code: 7SEV7J4R1U
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

acamprosate calcium - FDA Drug Approval Details